Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.
1. India’s drug regulator, under the Ministry of Health and Family Welfare, has directed the Indian Pharmacopoeia Commission to review safety data for GLP-1 weight-loss drugs. The Drug Consultative Committee also recommended stricter oversight and action against surrogate advertising, signaling tighter compliance and pharmacovigilance requirements for pharma companies amid expected generic market expansion.
Source: shortlink.uk/1seh
2. Bombay High Court has granted interim relief to an Indian pharmaceutical company in a trademark dispute, restraining a Kenyan company and its Indian manufacturer from using a mark phonetically similar to the plaintiff’s anti acidity drug. The court emphasized likelihood of confusion and affirmed infringement applies to exported goods.
Source: shortlink.uk/1n062
3. The Jan Vishwas Bill, 2026 proposes amendments to 79 Central Acts, decriminalising 717 minor offences and introducing graded penalties. In the health sector, key laws replace imprisonment with monetary penalties, aiming to reduce litigation, ease compliance for MSMEs, streamline regulatory processes, and improve the overall ease of doing business.
Source: shortlink.uk/1n06e
4. The Central Drugs Standard Control Organisation (CDSCO) is considering a proposal to debar entities whose drug licences have been cancelled from reapplying, in order to prevent repeat violations and regulatory circumvention. The proposal, discussed by the Drug Consultative Committee (DCC), also includes public disclosure of inspection findings to strengthen compliance and enforcement.
Source: shortlink.uk/1sehV
5. United States has imposed a 100% tariff on imported patented pharmaceuticals to strengthen domestic manufacturing. India’s pharma sector faces limited immediate impact as exports are mainly generics, which remain unaffected. However, companies dealing in patented drugs may encounter challenges, with potential long-term uncertainty over investments, market access, and shifting global supply chains.
Source: shortlink.uk/1sei4